| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	HC Wainwright & Co. analyst Patrick R. Trucchio maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target f...
 
																	D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target from $1 to $2.
 
																	
 
																	
 
																	The DECLARATION clinical trial is the company's Biologics License Application (BLA)-enabling, Phase 3 pivotal clinical tria...
 
																	Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Invivyd (NASDAQ:IVVD) with a Overweight rating and announces P...
 
																	
 
																	-SEC Filing
